The RNA Interference Effector Protein Argonaute 2 Functions as a Restriction Factor Against SARS-CoV-2

被引:5
|
作者
Lopez-Orozco, Joaquin [1 ]
Fayad, Nawell [1 ]
Khan, Juveriya Qamar [3 ]
Felix-Lopez, Alberto [2 ]
Elaish, Mohamed [1 ]
Rohamare, Megha [3 ]
Sharma, Maansi [3 ]
Falzarano, Darryl [4 ,5 ]
Pelletier, Jerry [6 ]
Wilson, Joyce [3 ]
Hobman, Tom C. [1 ,2 ,7 ]
Kumar, Anil [3 ]
机构
[1] Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB, Canada
[2] Univ Alberta, Fac Med & Dent, Dept Med Microbiol & Immunol, Edmonton, AB, Canada
[3] Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK, Canada
[4] Univ Saskatchewan, Vaccine & Infect Dis Org VIDO, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK, Canada
[6] McGill Univ, Dept Biochem, Montreal, PQ, Canada
[7] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB, Canada
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
innate immunity; coronaviruses; viral microRNAs; RNAi; Ago2; ANTIVIRAL IMMUNITY; STRESS GRANULES; DICER; VIRUSES; PHOSPHORYLATION; INHIBITION; EVOLUTION; RESPONSES; DEFENSE;
D O I
10.1016/j.jmb.2023.168170
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Argonaute 2 (Ago2) is a key component of the RNA interference (RNAi) pathway, a gene-regulatory sys-tem that is present in most eukaryotes. Ago2 uses microRNAs (miRNAs) and small interfering RNAs (siR-NAs) for targeting to homologous mRNAs which are then degraded or translationally suppressed. In plants and invertebrates, the RNAi pathway has well-described roles in antiviral defense, but its function in limiting viral infections in mammalian cells is less well understood. Here, we examined the role of Ago2 in replication of the betacoronavirus SARS-CoV-2, the etiologic agent of COVID-19. Microscopic analyses of infected cells revealed that a pool of Ago2 closely associates with viral replication sites and gene ab-lation studies showed that loss of Ago2 resulted in over 1,000-fold increase in peak viral titers. Replication of the alphacoronavirus 229E was also significantly increased in cells lacking Ago2. The antiviral activity of Ago2 was dependent on both its ability to bind small RNAs and its endonuclease function. Interestingly, in cells lacking Dicer, an upstream component of the RNAi pathway, viral replication was the same as in par-ental cells. This suggests that the antiviral activity of Ago2 is independent of Dicer processed miRNAs. Deep sequencing of infected cells by other groups identified several SARS-CoV-2-derived small RNAs that bind to Ago2. A mutant virus lacking the most abundant ORF7A-derived viral miRNA was found to be significantly less sensitive to Ago2-mediated restriction. This combined with our findings that endonu-clease and small RNA-binding functions of Ago2 are required for its antiviral function, suggests that Ago2-small viral RNA complexes target nascent viral RNA produced at replication sites for cleavage. Further studies are required to elucidate the processing mechanism of the viral small RNAs that are used by Ago2 to limit coronavirus replication.Crown Copyright & COPY; 2023 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
    Bates, Timothy A.
    Weinstein, Jules B.
    Farley, Scotland
    Leier, Hans C.
    Messer, William B.
    Tafesse, Fikadu G.
    CELL REPORTS, 2021, 34 (07):
  • [32] MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge
    Clement A. Meseda
    Charles B. Stauft
    Prabhuanand Selvaraj
    Christopher Z. Lien
    Cyntia Pedro
    Ivette A. Nuñez
    Amy M. Woerner
    Tony T. Wang
    Jerry P. Weir
    npj Vaccines, 6
  • [33] Cognitive functions and SARS-CoV-2 infection
    Talarowska, Monika
    NEUROPSYCHIATRIA I NEUROPSYCHOLOGIA, 2021, 16 (3-4): : 109 - 115
  • [34] Developing inhibitory peptides against SARS-CoV-2 envelope protein
    Bekdash, Ramsey
    Yoshida, Kazushige
    Nair, Manoj S.
    Qiu, Lauren
    Ahdout, Johnathan
    Tsai, Hsiang-Yi
    Uryu, Kunihiro
    Soni, Rajesh K.
    Huang, Yaoxing
    Ho, David D.
    Yazawa, Masayuki
    PLOS BIOLOGY, 2024, 22 (03)
  • [35] Monoclonal neutralizing antibodies against SARS-COV-2 S protein
    Cheng, Lin-Dong
    Li, Ping
    Lin, Yan-Chen
    Hu, Hui-Xiu
    Zhang, Ying
    Li, Hou-Feng
    Huang, Jing
    Tan, Li
    Ma, Ning
    Xia, Deng-Yun
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (02): : 681 - 689
  • [36] Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
    Tang, Qilong
    Owens, Raymond J.
    Naismith, James H.
    VIRUSES-BASEL, 2021, 13 (11):
  • [37] Impfung gegen SARS-CoV-2 bei KrebspatientenVaccination against SARS-CoV-2 in cancer patients
    Marie von Lilienfeld-Toal
    Christina Rieger
    Nicola Giesen
    Bernhard Wörmann
    Der Onkologe, 2021, 27 : 691 - 696
  • [38] SARS-CoV-2 infection and cancer Evidence for and against a role of SARS-CoV-2 in cancer onset
    Stingi, Aureliano
    Cirillo, Luca
    BIOESSAYS, 2021, 43 (08)
  • [39] Timing vaccination against SARS-CoV-2
    Barnoud, Coline
    Wang, Chen
    Scheiermann, Christoph
    CELL RESEARCH, 2021, 31 (11) : 1146 - 1147
  • [40] Adaptive immunity against SARS-CoV-2
    Combadiere, Behazine
    M S-MEDECINE SCIENCES, 2020, 36 (10): : 908 - 913